Skip to content
Screener

Pre-Tax Income at other companies

Pfizer logo
PfizerPFE
-$653M-121%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$284.9M+39.0%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
-$166.3M-890%
Viatris logo
ViatrisVTRS
-$64M+70.5%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
-$8.06M+64.9%
Opko Health logo
Opko HealthOPK
-$13.4M+91.8%

Other financials

Income statement

See full
Revenue$183.9M+5.4%
Gross profit$93.5M+8.1%
Operating income$39.7M-5.8%
Net income$30.3M-2.2%
EPS (diluted)$0.67+4.7%

Balance sheet

See full
Cash & equivalents$223.6M+19.1%
Total debt$688.5M+5.0%
Total equity$445.5M
Total assets$1.7B+8.0%

Cash flow

See full
Operating cash flow$51.3M+44.2%
CapEx$8.6M-18.7%
Free cash flow$42.7M+70.7%

Valuation

See full
Market cap$916.25M-28.0%
Enterprise value$1.38B-20.6%
P/E11.7×+2.2×
P/S1.3×-0.5×

Profitability

See full
Gross margin47.7%-2.2pp
Operating margin15.7%-9.5pp
Net margin10.8%-7.9pp
FCF margin20.9%+5.4pp

Returns & leverage

See full
Return on equity14.7%
Debt / equity0.2×
Current ratio2.4×-0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:50 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001297184-26-000047
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Interest expense(6,659)(6,281)(13,212)(12,567)
Other income (expenses), net3,1871,5113,762(723)
Total non-operating expenses, net(1,185)(2,849)(4,763)(9,280)
Income before income taxes38,54439,33548,59670,197
Income tax provision8,1968,30511,82813,882
Net income$30,348$31,030$36,768$56,315
Net income per share:
Basic$0.69$0.66$0.83$1.19

Item 1. Financial Statements (unaudited)

FAQ

What is Amphastar Pharmaceuticals's pre-tax income?
Amphastar Pharmaceuticals (AMPH) reported pre-tax income of $38.54M in Q2 2026.
How has Amphastar Pharmaceuticals's pre-tax income changed year-over-year?
Amphastar Pharmaceuticals's pre-tax income decreased by 2.0% year-over-year, from $39.34M to $38.54M.
What is the long-term trend for Amphastar Pharmaceuticals's pre-tax income?
Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's pre-tax income has grown at a 10.1% compound annual growth rate (CAGR), from $84.14M to $123.62M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Amphastar Pharmaceuticals's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude